OCTALFA

Sirius NeoSight is a biotechnology and pharmaceutical company focused on the early detection and treatment of subclinical neo-cancers. It develops healthcare technology software that serves clients in the healthcare sector, utilizing patented technology to measure the fluidity of membranes specifically in oncology. This innovative approach enables the detection and purification of Circulating Tumor Cells, contributing to advancements in personalized medicine. Through its unique offerings, Sirius NeoSight aims to improve cancer diagnostics and therapeutic strategies, ultimately enhancing patient care and outcomes in oncology.

ORPHELIA Pharma SA is a French pharmaceutical company dedicated to the development and marketing of pediatric formulations targeting epilepsy, neurodegenerative diseases, and metabolic disorders. Founded in 2007 and headquartered in Paris, the company focuses on creating safe, reliable, and child-friendly medicines. Its product pipeline includes ORP-001, a reformulation of the antiepileptic drug vigabatrin; ORP-002, aimed at treating Rett syndrome; ORP-003, another reformulation of an existing antiepileptic; and ORP-006, targeting a specific type of neonatal epileptic encephalopathy. ORPHELIA Pharma seeks to enhance the efficacy of essential medicines for children, particularly in the context of rare pediatric diseases and oncology. The company was previously known as TargeOn SAS before rebranding in October 2015.

Mathym is a biomedical company specializing in the development and supply of colloidal nanomaterials, particularly for dental applications. The company creates nano-dispersions that enhance the properties of various medical devices, ensuring a stable and uniform distribution of nanoparticles in liquids. In addition to dental applications, Mathym's products cater to multiple industries, including fine ceramics, photonics, displays, and semiconductor manufacturing. By providing these advanced materials, Mathym supports researchers and manufacturers in achieving improved performance and reliability in their applications.

ORPHELIA Pharma SA is a French pharmaceutical company dedicated to the development and marketing of pediatric formulations targeting epilepsy, neurodegenerative diseases, and metabolic disorders. Founded in 2007 and headquartered in Paris, the company focuses on creating safe, reliable, and child-friendly medicines. Its product pipeline includes ORP-001, a reformulation of the antiepileptic drug vigabatrin; ORP-002, aimed at treating Rett syndrome; ORP-003, another reformulation of an existing antiepileptic; and ORP-006, targeting a specific type of neonatal epileptic encephalopathy. ORPHELIA Pharma seeks to enhance the efficacy of essential medicines for children, particularly in the context of rare pediatric diseases and oncology. The company was previously known as TargeOn SAS before rebranding in October 2015.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Nightswapping is a peer-to-peer accommodation exchange platform that connects a community of over 150,000 members who swap nights to travel and stay for free in each other's homes. By eliminating financial transactions, the platform fosters authentic experiences for both hosts and travelers while avoiding legal complications. Members can either exchange their nights for free stays in over 160 countries or convert their nights into real money if desired. Additionally, for those uncertain about their travel destinations, the platform offers suggestions for unexpected and exciting places to visit, enhancing the overall travel experience.

Mathym is a biomedical company specializing in the development and supply of colloidal nanomaterials, particularly for dental applications. The company creates nano-dispersions that enhance the properties of various medical devices, ensuring a stable and uniform distribution of nanoparticles in liquids. In addition to dental applications, Mathym's products cater to multiple industries, including fine ceramics, photonics, displays, and semiconductor manufacturing. By providing these advanced materials, Mathym supports researchers and manufacturers in achieving improved performance and reliability in their applications.

e(ye)BRAIN SA is a medical company specializing in the development and manufacturing of eye trackers designed for the diagnosis of neurological and psychiatric diseases. Founded in 2008 and based in Paris, France, the company offers two primary products: EyeBrain T1 and EyeBrain T2. The EyeBrain T1 allows users to record eye movements, while the EyeBrain T2 incorporates advanced algorithms to capture both eye and head movements. These recorded movements are then analyzed using the MeyeEval software. In addition to its product offerings, e(ye)BRAIN provides advisory, paradigm development, training, and support services to its clients, enhancing their capabilities in clinical research and functional exploration of both healthy and diseased brains.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Laboratories JUVISE Pharmaceuticals is a multinational pharmaceutical company that specialises in acquiring, manufacturing and marketing treatments offering great therapeutic potential for patients around the world. Following the sale of Lynapharm laboratories to the Italian pharmaceutical group Sigma-Tau in 2008, Mr Mascha established JUVISE Pharmaceuticals company as an international pharmaceutical subsidiary of the JUVISE group. JUVISE Pharmaceuticals is a pharmaceutical company accredited by the ANSM, French National Agency for the Safety of Medicines and Health Products. The company specialises in manufacturing and marketing pharmaceutical products to treat cardiologic, psychiatric, rheumatic and respiratory/ENT conditions and also fertility/sexual matters. JUVISE Pharmaceuticals currently markets 8 speciality pharmaceutical products: Esidrex®, Sintrom®, Digoxin®, Entumin®, Insidon®, Lumirelax®, Calmixène®, Extovyl®. It also markets two food supplements: Proxeed®Plus and Proxeed®Women. These are sold in a total of 57 countries.

Graftys is an early-stage company based in Aix-en-Provence, France, specializing in advanced bone biologics. The company develops synthetic bone biomaterials intended for use in reconstructive orthopedic surgery. Graftys offers a range of innovative, safe, and fully injectable calcium phosphate bone graft substitutes tailored for specific clinical applications. This focus allows the company to provide high-quality and standardized products that enhance outcomes in bone reconstructive and trauma surgery, addressing the needs of both healthcare professionals and patients.

Orega Biotech SAS is a biotechnology company founded in 2010 and based in Écully, France, specializing in the development of immunotherapeutics for cancer treatment. The company focuses on creating monoclonal antibodies that target the tumor microenvironment and modulate the activity of regulatory T cells. By leveraging scientific insights in tumor immunology, Orega Biotech aims to improve the efficacy of cancer immunotherapy, enhance response rates, and ultimately increase patient survival. Its target discovery program is dedicated to identifying and validating novel clinically relevant cancer targets, contributing to advancements in therapeutic strategies for cancer.

Docea Power SAS specializes in developing and marketing software solutions for power and thermal analysis at the architectural level. Based in Moirans, France and founded in 2006, the company offers Aceplorer, a software tool designed for modeling, exploring, and optimizing the power and thermal behavior of diverse electronic system architectures. The Aceplorer solution accommodates heterogeneous systems composed of digital, analog, or mixed signal blocks and supports various levels of modeling complexity. Additionally, Docea Power provides AceThermalModeler, which generates compact thermal models for systems on chips, 3D ICs, systems in package, and complete circuit boards. The company also offers training and consultancy services to its clients, which include OEMs, SiP and SoC manufacturers, as well as IP and IC providers. Docea Power serves multiple sectors, including wireless, automotive, consumer electronics, aerospace, computing, and medical markets. As of 2015, the company operates as a subsidiary of Intel Corporation.

Glycode SAS, a biotechnology company, operates in the field of protein glycosylation in France. It provides and licenses GlycodExpress, a yeast based technological platform for the production of recombinant therapeutic glycoproteins for therapeutic purposes, such as antibodies, EPOs, and growth factors, as well as allows humanization of N-glycosylation in Saccharomyces cerevisiae. The company also offers on-demand production and purification services, from the conception and synthesis of optimized expression vectors for protein expression in glycoengineered yeasts to the early steps of production process. Glycode SAS serves biotechnology and pharmaceutical companies. The company was founded in 2004 and is based in Uzerche, France.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Antagene is a French biotechnology company headquartered in Limonest, France, specializing in veterinary genetic testing for animals, particularly dogs and cats. The company develops and sells DNA tests that identify genetic diseases, such as night blindness and retinal atrophy, thereby promoting animal health and welfare. Antagene's offerings enable breeders to select healthy breeding animals and reduce the risk of passing on serious genetic disorders to offspring. By focusing on early detection and genetic profiling, Antagene aims to improve traceability and management within breeding practices, ultimately contributing to the prevention of genetic diseases in companion animals. As of 2016, Antagene operates as a subsidiary of CERBA VET, enhancing its capabilities in veterinary diagnostics.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.